PepGen Inc PEPG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
-
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
-
Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems
-
FDA Puts PepGen's Trial for Myotonic Dystrophy Treatment on Hold
Trading Information
- Previous Close Price
- $2.70
- Day Range
- $2.62–2.94
- 52-Week Range
- $1.31–7.80
- Bid/Ask
- $2.93 / $2.88
- Shares Outstanding
- 69.26M
- Market Cap
- $198.77M
- Volume/Avg
- 3M / 896,981
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.pepgen.com
Valuation
|
Metric
|
PEPG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.66 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PEPG
|
|---|---|
Quick Ratio | 13.02 |
Current Ratio | 13.36 |
Interest Coverage | — |
Quick Ratio
PEPG
Profitability
|
Metric
|
PEPG
|
|---|---|
Return on Assets (Normalized) | −41.41% |
Return on Equity (Normalized) | −49.80% |
Return on Invested Capital (Normalized) | −46.33% |
Return on Assets
PEPG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vH&f^?> | LOCK|bVlN | $130B | |||
| Moderna Inc
MRNA
| LOCK|>yMfK%M | LOCK|YP | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|lx!tGY | LOCK|ZvV# | $83B | |||
| argenx SE ADR
ARGX
| LOCK|C@&%kJV | LOCK|P#> | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|q&tB<B | LOCK|>Dd | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?f>Vg%@ | LOCK|%wp&! | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?mbbtz< | LOCK|WQskm | $28B | |||
| Incyte Corp
INCY
| LOCK|S!!g$f | LOCK|HJw | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|rFq%ym? | LOCK|@X! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|t?Srj^< | LOCK|vD | $14B |
United States